Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Albireo, An Ipsen Company

Clinical trials sponsored by Albireo, An Ipsen Company, explained in plain language.

Now part of Ipsen S.A. IPN EURONEXT PARIS

A biopharmaceutical company focused on liver diseases, now part of Ipsen.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Not yet finished but already full! 2 Completed 2 Terminated 1

New drug A3907 tested for rare liver disease, study halted early

Disease control Terminated

This study tested a drug called A3907 in 18 adults with Primary Sclerosing Cholangitis (PSC), a rare liver disease. The goal was to check if the drug is safe and how the body processes it. The study was stopped early, so results are limited.

Phase: PHASE2 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control

Last updated Jun 27, 2026 12:30 UTC